Related Experiment Video

Updated: Mar 13, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.5K

Treatment strategies according to genotype for chronic hepatitis B in children

Seung Man Cho1, Byung-Ho Choe2

  • 1Department of Pediatrics, Dongguk University School of Medicine, Gyeongju, Korea.

Annals of Translational Medicine
|October 21, 2016
PubMed

Insights

Pediatric chronic hepatitis B (CHB) treatment aims to prevent liver disease complications. Optimal therapy, including nucleos(t)ide analogues (NAs), depends on patient factors and hepatitis B virus (HBV) genotype.

Area of Science:

  • Hepatology
  • Pediatric Gastroenterology
  • Virology

Background:

  • Chronic hepatitis B (CHB) infection in children poses a risk for long-term liver disease, including hepatocellular carcinoma (HCC).
  • Effective management of pediatric CHB is crucial to mitigate disease progression and prevent serious complications.
  • Understanding the nuances of CHB in pediatric populations is essential for developing targeted treatment strategies.

Approach:

  • This review synthesizes current knowledge on pediatric CHB treatment, focusing on therapeutic approaches and considerations.
  • The article examines treatment selection criteria, including patient stratification and timing of intervention to minimize viral resistance.
  • Emphasis is placed on the role of newly developed nucleos(t)ide analogues (NAs) in managing CHB in children.

Key Points:

  • Treatment decisions for pediatric CHB are influenced by geographical region (Western/Eastern), hepatitis B virus (HBV) genotype, healthcare accessibility, and national economic status.
  • Identifying the specific HBV genotype is critical for optimizing therapeutic efficacy and preventing the development of drug resistance.
  • Nucleos(t)ide analogues (NAs) demonstrate significant potency in treating CHB in pediatric patients.

Conclusions:

  • Personalized treatment strategies based on HBV genotype are recommended for improved outcomes in pediatric CHB.
  • Adherence to established treatment guidelines and genotypic determination are key to enhancing the effectiveness of NA therapy.
  • Further research and clinical application are needed to refine pediatric CHB management protocols.

Keywords:
Childrenchronic hepatitis B (CHB)genotypetreatment

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.7K
Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

3.5K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
349
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
309
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.2K
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
55
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
626
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
247